A Role for Germline Variants in Multiple Myeloma?

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2024-11-01 DOI:10.1158/2643-3230.BCD-24-0226

Brian A Walker

引用次数: 0

Abstract

In Blood Cancer Discovery, Thibaud and colleagues report the incidence of pathogenic germline variants (PGV) in patients with multiple myeloma and that these PGVs are associated with DNA repair pathway genes, including BRCA1 and BRCA2. They find an association of patients with PGVs and previous family or personal history of cancer, and that these patients are diagnosed slightly earlier than those without PGVs. Patients with PGVs had a longer progression-free survival than those without PGVs when they received high-dose melphalan and autologous stem cell transplant, providing a therapeutic rationale for diagnostic germline testing in myeloma. See related article by Thibaud et al., p. 428.

查看原文本刊更多论文

种系变异在多发性骨髓瘤中的作用？

Thibaud 及其同事在《血癌发现》（Blood Cancer Discovery）杂志上报告了多发性骨髓瘤患者中致病性种系变异（PGVs）的发生率，这些变异与 DNA 修复通路基因（包括 BRCA1 和 BRCA2）有关。他们发现，PGVs 患者与既往家族或个人癌症病史有关，而且这些患者的确诊时间略早于无 PGVs 患者。在接受大剂量美法仑和自体干细胞移植时，有PGVs的患者比没有PGVs的患者无进展生存期更长，这为骨髓瘤的诊断性种系检测提供了治疗依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.